4/20 marijuana holiday is here. What are Florida weed laws? Find medical dispensaries in PBC
As families gather to celebrate Easter today, others across the country are marking a different kind of holiday, 4/20, a day widely recognized by marijuana enthusiasts. Whether it's the distinct smell lingering in the air or eye-catching dispensary billboards across Palm Beach County, cannabis culture is hard to miss. But it raises a big question: Is marijuana actually legal in Florida?
No, you cannot.
Despite receiving 55.9% of votes, Amendment 3 did not achieve the 60% threshold needed to pass during the 2024 General Election. It saw 5,934,139 votes in total.
Medical marijuana is legal in Florida for residents diagnosed with a specific set of conditions who have applied for and received a Medical Marijuana ID Card or caregivers who have received a Medical Marijuana Caregiver Card.
Here are following conditions eligible for and to receive a Medical Marijuana Card:
Cancer
Epilepsy
Glaucoma
HIV (human immunodeficiency virus)
AIDS (Acquired immune deficiency syndrome)
PTSD (post-traumatic stress disorder)
ALS (amyotrophic lateral sclerosis)
Crohn's disease
Parkinson's disease
Multiple sclerosis
Comparable medical conditions or status to the above
A terminal condition
Chronic nonmalignant pain
Palm Beach County is home to over 30 licensed medical marijuana dispensaries, offering a range of cannabis products to qualified patients. These dispensaries are spread across various cities, including West Palm Beach, Lake Worth, Boynton Beach, Delray Beach, Boca Raton, and Jupiter. Notable dispensary chains operating in the county include Trulieve, Curaleaf, MÜV, Surterra Wellness, Green Dragon, and Sunnyside.
No. The state of Florida does not offer reciprocity, although a bill filed for this year's legislative session would change that if passed.
Without a Medical Marijuana Card (or Medical Marijuana Caregiver Card, for people assisting medical marijuana patients who are minors or who need help), if you are caught with pot, marijuana advocacy group NORML lists the following penalties under Florida Statutes:
Possessing 20 grams or less: first-degree misdemeanor, up to one year in jail and maximum $1,000 fine.
Possession of paraphernalia: Misdemeanor, up to one year in jail and maximum $1,000 fine.
Possessing marijuana within 1,000 feet of a school, college, park or other specified areas: Felony, mandatory three-year sentence and maximum $10,000 fine.
Possessing from 20 grams: to 25 pounds: Felony, up to five years in jail and maximum $5,000 fine.
Possessing from 25 to 2,000 pounds of marijuana: First-degree felony, from three to 15 years in jail and $25,000 fine.
Possessing from 2,000 to 10,000 pounds of marijuana: First-degree felony, from seven to 30 years and $50,000 fine.
Possessing more than 10,000 pounds of marijuana: First-degree felony, from 15 to 30 years and $200,000 fine.
However, many communities and municipalities have decriminalized possession of up to 20 grams or marijuana, meaning if you're busted you'll get a fine (which will go up each time) and you may be required to attend a drug education program or do community service.
Areas that have decriminalized pot include Alachua County, Broward County, Cocoa Beach, Hallandale Beach, Key West, Miami Beach, Miami-Dade County, Orlando, Osceola County, Palm Beach County, Port Richey, Sarasota, Tampa and Volusia County.
Only licensed medical marijuana dispensaries may sell marijuana in the state of Florida. Even if the proposed recreational amendment passes next year, you still would have to buy your pot at a licensed dispensary.
People charged with selling marijuana can face the following:
25 grams or less, without renumeration: Misdemeanor, maximum 1 year in jail, $1,000 fine.
20 grams to 25 pounds: Felony, maximum 5 years in jail, $5,000 fine.
25 to less than 2,000 pounds or 300-2,000 plants: Felony, three to 15 years, maximum $25,000 fine.
2,000 to less than 10,000 pounds or 2,000-10,000 plants: Felony, seven to 30 years, maximum $50,000 fine.
10,000 pounds or more: Felony, 15 to 30 years, maximum $200,000 fine.
If within 1,000 feet of a school, college, park, or other specified areas: An additional 3-15 years, $10,000 fine
Assorted different types of so-called "diet weed" cannabinoids such as delta-8, delta-9, delta-10 and THC-O, which are derived from hemp and not marijuana and contain lower levels of THC, are sort-of legal here under the 2018 federal Farm Bill that allows farmers to grow industrial hemp.
Last year, the Florida Legislature passed a bill, SB 1698, that effectively banned delta-8 and delta-10 products and placed a 5-milligram-delta-9 concentration limit per serving but Gov. Ron DeSantis vetoed it, reportedly to protect small businesses. However, they remain federally illegal.
This article originally appeared on Palm Beach Post: What 4/20 looks like in Florida: Legal limits, marijuana dispensaries
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Opportunities in the Central Nervous System (CNS) Therapeutics Market: Revenues Forecast to Reach US$156.5 Billion by 2030
Growth is driven by the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, and schizophrenia, fueled by aging populations and heightened mental health awareness. North America leads the market, with significant growth anticipated in Asia-Pacific due to rising mental health consciousness and improved healthcare access. Central Nervous System Therapeutics Market Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics - Global Strategic Business Report" has been added to global market for Central Nervous System Therapeutics was valued at US$107 Billion in 2024 and is projected to reach US$156.5 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Central Nervous System Therapeutics market. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Allergan plc, Anavex Life Sciences Corp., AstraZeneca plc, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. The global CNS therapeutics market is growing due to increasing disease burden, heightened awareness of mental and neurological health, and the rapid advancement of therapeutic science. Unmet needs across multiple CNS indications, combined with demographic pressures and healthcare digitization, are generating sustained demand for both novel and reformulated therapies. Public and private sector investments in neuroscience research, along with regulatory support for orphan drug development and accelerated pathways, are further incentivizing companies are expanding pipelines through acquisitions, collaborations, and AI-enabled drug discovery platforms focused on CNS targets. At the same time, patient advocacy, digital care models, and personalized treatment paradigms are shifting the industry toward more holistic, outcomes-driven approaches. As complexity in CNS care deepens and precision treatment becomes more attainable, a defining question shapes the market's future: Can CNS therapeutics continue to evolve through biomarker-guided innovation, cross-disciplinary care models, and scalable delivery platforms while addressing the dual challenge of clinical uncertainty and global accessibility?Key Insights: Market Growth: Understand the significant growth trajectory of the Analgesics segment, which is expected to reach US$46.6 Billion by 2030 with a CAGR of a 8.6%. The Anti-Cholinergic Agents segment is also set to grow at 4.6% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $29.2 Billion in 2024, and China, forecasted to grow at an impressive 10.6% CAGR to reach $32.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Questions Answered: How is the Global Central Nervous System Therapeutics Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 44 companies featured in this Central Nervous System Therapeutics market report include: AbbVie Inc. Allergan plc Anavex Life Sciences Corp. AstraZeneca plc Biogen Inc. Bristol Myers Squibb Cipla Limited Dr. Reddy's Laboratories Ltd. Eli Lilly and Company GlaxoSmithKline plc H. Lundbeck A/S Johnson & Johnson Lupin Limited Merck & Co., Inc. Novartis AG Otsuka Pharmaceutical Co., Ltd. Pfizer Inc. Roche Holding AG Takeda Pharmaceutical Company Ltd. Teva Pharmaceutical Industries Ltd. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 395 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $107 Billion Forecasted Market Value (USD) by 2030 $156.5 Billion Compound Annual Growth Rate 6.5% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Central Nervous System Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Prevalence of Alzheimers, Parkinsons, and Epilepsy Fuels Demand for CNS Drug Innovation Biologics, Gene Therapies, and Small Molecules Converge in Development Pipelines for CNS Disorders Cross-BBB Delivery Technologies and Neurotargeted Carriers Address Long-Standing Bioavailability Barriers Psychiatric Disorders Like Depression and Bipolar Drive Growth in Multimodal CNS Treatment Strategies Digital Therapeutics and CNS Drug Monitoring Tools Expand Clinical Management Capabilities Patient-Centered Outcome Measures Gain Priority in CNS Trial Designs and Payer Decisions High Unmet Need in Rare Neurological Conditions Spurs Orphan Drug Development Activity Aging Demographics and Lifestyle Shifts Expand CNS Therapeutic Demand Across Regions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Central Nervous System Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Boston Globe
7 hours ago
- Boston Globe
Trump turned 79 this weekend and will be 82 at the end of his term. How old is too old?
Write to us at . To subscribe, . TODAY'S STARTING POINT The president is an old man. He sometimes mixes up names or garbles his words. Some voters worry that age is affecting his performance in arguably the world's most demanding job. Those sentences are true today: Donald Trump, who turned 79 on Saturday, is the oldest president ever at this point in his term. But they've also been true for the past eight years, both during Trump's first term and during Joe Biden's. At the end of Trump's second, he will be the oldest president ever — and among the oldest leaders Advertisement Many politicians, like many people, remain sharp and spry into old age. And older leaders can bring strengths: More experience and longtime ties with the voters they represent. But age also brings health vulnerabilities. Since the first members of Congress convened in 1789, Today's newsletter explains what we know about Trump's health and the ongoing debate around older elected officials. Advertisement The age of Trump Aging increases the risk of getting cancer, having heart attacks and strokes, and developing Alzheimer's, Parkinson's, and other neurodegenerative diseases. By the time Americans reach 65, about 90 percent suffer from at least one chronic condition, said Dr. Eric Topol, a cardiologist who studies aging. Topol published a book last month, ' On the other hand, Trump doesn't drink, and his wealth and office give him access to top-tier medical care. Trump's doctor calls his health ' Trump has for years given rambling speeches and misstated facts, which could make it hard to tell if his faculties are changing. Still, he often appears more tired today than he did in his first term. During the 2024 campaign, Trump warned that Biden would 'plunge the world into World War II' and mixed up Nancy Pelosi and Nikki Haley. Since starting his second term, Trump has Advertisement Right now, Americans don't seem too concerned about Trump's age and health: less than a third say those factors ' Age-old debate Being old, of course, is no guarantee of infirmity. And casually dismissing aging lawmakers also risks stoking stigma against older Americans in general. But Biden's withdrawal from the 2024 presidential election after a Some argue that younger politicians offer a clear break with the past and are more attuned to younger voters' concerns. Over the weekend, Representative Alexandria Ocasio-Cortez of New York, 35, Most voters, though, may have other ideas. Many Advertisement Potential guardrails Francis Shen, a University of Minnesota law professor who studies aging and the law, thinks strict age limits would bar older politicians who remain capable — and that the public debate should be about cognitive ability, not the year on a politician's birth certificate. Instead, he argues, Congress should require candidates for federal office to take and disclose cognitive assessments, much as it requires financial disclosures. Topol predicts that medical advances will soon enable routine testing to determine how vulnerable someone is to age-related disease, allowing political candidates to release more detailed metrics about their current and future health. Still, there's a long history of presidents of both parties That means if Trump experiences cognitive decline in office, it might be hard to know for sure. 🧩 6 Across: 69° POINTS OF INTEREST A person golfs at Puttshack in Seaport, which has seen higher traffic than usual on rainy weekends. Suzanne Kreiter/Globe Staff Boston and New England A broken housing market: The price of the typical Massachusetts home is now Measles: A traveler sick with the highly contagious virus visited a Boston hotel, the Museum of Fine Arts, and Logan Airport earlier this month, Pièce de résistance: A 12-year-old who recreated the Boston Tea Party using more than 1,000 LEGO bricks will represent the city Rain check: A string of washout weekend days has Massachusetts residents [Redacted for a family paper]: Maine's newly redesigned license plate features a pine tree. Some drivers Trump administration Israel vs. Iran: Israel had a chance to assassinate Iran's supreme leader over the weekend, but US officials told their Israeli counterparts that Trump opposed doing so. Israel and Iran continued to exchange missiles. ( Pick and choose: After telling ICE to stop targeting undocumented workers at farms, restaurants, and hotels, Trump directed the agency to prioritize deportations from Democratic-run cities. ( G7 summit: Trump will meet with Canadian Prime Minister Mark Carney today. They may discuss trade negotiations ahead of talks with five other world leaders near Calgary, Alberta. ( 'No Kings': Anti-Trump protests in Boston and hundreds of other cities across the country drew millions of attendees, organizers said. Trump vs. Harvard: A judge will hear arguments today over Trump's effort to BESIDE THE POINT 🗓️ For your calendar: A Juneteenth whiskey tasting, the 250th anniversary of the Battle of Bunker Hill, an audiobook walking club, and more 🏈 Sportswashing: The NFL is selling flag football to bougie parents ( Advertisement 🎥 Happy 50th: Read our film critic's memories of seeing 'Jaws' 👨🦲 Misters Worldwide: Pitbull's fans dress like him at his concerts. It's hysterical to see that many people in bald caps. ( ❤️ Love Letters: She's on all the dating apps, but Get outside: The Coolidge is hitting the road this summer. Here's where you can watch films curated by the nonprofit Brookline cinema on the Greenway and elsewhere al fresco. ( 🪦 RIP: Graham Gund, an architect and philanthropist who shaped Boston's skyline and art museums, Thanks for reading Starting Point. This newsletter was edited by ❓ Have a question for the team? Email us at ✍🏼 If someone sent you this newsletter, you can 📬 Delivered Monday through Friday. Ian Prasad Philbrick can be reached at


Business Wire
12 hours ago
- Business Wire
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two Phase II trials and their open-label extensions, combined with the favorable safety and tolerability profile of prasinezumab," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We also recognize the substantial need for new treatment options, and the totality of data suggest that prasinezumab may have the potential to become the first disease-modifying treatment for people with Parkinson's disease." Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing. About prasinezumab Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. Data from the Phase IIb PADOVA study suggest the possible clinical benefit of prasinezumab on top of effective symptomatic treatment in early-stage Parkinson's disease. PADOVA investigated prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01], although the study missed statistical significance (p=0.0657). In a pre-specified analysis, the effect of prasinezumab was more pronounced in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99], p=0.0431 (nominal). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Trends towards reduced motor progression at 104 weeks (two years) were observed, showing 30-40% relative reduction versus placebo across the overall and levodopa-treated populations. Prasinezumab continues to be well tolerated and no new safety signals were observed in the study. The safety database for prasinezumab consists of data from more than 900 Parkinson's disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson's disease. About Parkinson's disease Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells, and the development of motor and non-motor symptoms that may appear years before diagnosis. Today, Parkinson's disease affects over 10 million people worldwide. The prevalence of Parkinson's disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available today, having a significant impact on people's quality of life; however, no available symptomatic therapies slow down or stop the clinical progression of Parkinson's disease and the effects wear off over time as the disease progresses. Genentech and Roche are evaluating multiple approaches to slow down disease progression and potentially prevent Parkinson's disease that involve targeting underlying disease processes such as aggregated α-syn production, lysosomal dysfunction and neuroinflammation. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit